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How can we decide a fair allocation of healthcare resources during a pandemic? 
 
ABSTRACT Whenever the government makes medical resource allocation 
choices, there will be opportunity costs associated with those choices: some patients will 
have treatment and live longer, while a different group of patients will die prematurely. 
Because of this, we have to make sure that the benefits we get from investing in treatment 
A are large enough to justify the benefits forgone from not investing in the next best 
alternative, treatment B. There has been an increase in spending and reallocation of 
resources during the COVID-19 pandemic that may have been warranted given the 
urgency of the situation. However, these actions do not bypass the opportunity cost 
principle although they can appear to in the short-term, since spending increases cannot 
continue indefinitely and there are patient groups who lose out when resources are 
redirected to pandemic services.  Therefore, policy makers must consider who bares the 
cost of the displaced healthcare resources. Failure to do so runs a risk of reducing overall 
population health while disproportionally worsening health in socially disadvantaged 
groups. We give the example of ethnic minorities in England who already had the worst 
health and, due to structural injustices, were hardest hit by the pandemic and may stand 
to lose the most when services are reallocated to meet the resource demands of the crisis. 
How can we prevent this form of health inequity? Our proposal is forward-looking: we 
suggest that the government should invest our resources wisely while taking issues of 

















The COVID-19 pandemic has posed a serious challenge for the UK government, 
and, in particular, for the NHS. Both primary and secondary care in the UK were 
experiencing overcrowding, shortage of staff and excessive waiting times for patients 
before the pandemic. The situation was made much worse during the pandemic because 
of the additional problems created by a limited supply of ventilators and personal 
protective equipment available to healthcare workers. Therefore, a quick response was 
necessary. However, the government’s response was met with criticism and many have 
pointed out that the lockdown restrictions and cancellation of services have caused 
collateral damage. The government has been accused of transforming the NHS into a 
“Covid-only service”, where most of urgent health care services such as cancer 
diagnostic tests and cancer treatments have been postponed. This alone has had and will 
continue to have a huge impact on mortality and morbidity. In the UK, over 1 million 
patients had their surgery postponed, all non-urgent surgery was suspended for at least 3 
months in England and at least 40, 000 people did not receive their cancer treatment.1 
Mental health services have also been completely shut down across England. The 
Royal College of Psychiatrists were worried they may not be able to face and deal 
efficiently with the “tsunami of referrals” they expect after the pandemic.2 While in May 
this was merely a prediction, it has now become a fact. On the 1st of November 
psychologists have published a letter to policy makers detailing the devastating mental 
health effects that lockdown restrictions have had on the UK population, in particular on 
children and adolescents: they report a significant increase in depression, self-harm and 
child suicide.3 
The situation has created the impression that governments have made resource 
allocation decisions in an arbitrary manner, whereby only certain people have access to 
health resources.4 However, situations of crisis require tough decisions and prioritisation 
of resources. For instance, in a recent article Chiara Mannelli speaks of the difficult 
decision that doctors had to make in Italy about which patients should be provided with 
a ventilator.5  Given that there weren’t enough ventilators for all patients, doctors found 
themselves in the position of “playing God” to decide whose life to save and who to let 
die.6 As she points out, it is a fact of our society that we do not have the resources to treat 
everyone, this is “something we already know” but “we just try to forget about it”.5  
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But what does it mean “not to forget about it”? It implies a concern with issues of 
cost-effectiveness: we need to invest our limited resources wisely. This means two 
things: a) We should use resources to save the lives which can be saved; to do this, we 
need good evidence that the treatment is clinically effective, instead of wasting money 
on futile treatment. b) We should invest where we can do the most good and save the 
most lives, and this in effect means that we have a duty to also consider lives which could 
be saved in the future. This, indeed, is the aim of our national health care system: to 
generate health that is equitably distributed.7  
However, something unprecedented has happened in the UK. In a rare act, during 
the COVID-19 pandemic, the government has made decisions that appear to put people 
first and save lives, and responded to the crisis with no apparent reference to costs or 
forgone benefits elsewhere in the healthcare system and outside of it. Contrast this with 
the immediate introduction of a set of austerity policies in the aftermath of 2008 global 
financial crisis which was justified by minsters in economic and ethical terms; reducing 
the budget deficit was presented to the public as an imperative to promote growth and 
avoid an unfair tax burden on the next generation. Nevertheless, linking economic 
spending to a future distribution of resources in  such difficult times as a pandemic seems 
inhumane and perhaps politically unwise.  
But was it the right thing to do and should we do the same in the future whenever 
another crisis comes along? Although it seems that the decision expresses concern about 
issues of fairness, ignoring the principles of cost-effectiveness can itself lead to serious 
injustice, disadvantaging the very people we want to protect. In order to move forward 
and progress in a way which promotes fairness we suggest we need to pay attention to 
two things: who was mostly affected by the COVID-19 crisis and why? Who are the 
patients most likely to bear the true opportunity costs of the crisis?  
Our argument will take the following form. We start with the plausible premise that 
a crisis will cause an increase in spending or reallocation of resources during a pandemic. 
We then argue that allocating resources based on a cost effectiveness-analysis is better, 
all things considered, than an arbitrary increase in spending, and this is because of the 
principle of opportunity cost. This principle, we argue, ensures that resources are 
allocated more fairly, that is, in a way which guarantees we save lives instead of 
unnecessarily sacrificing people’s health. Despite this, we then turn to argue that a cost-
equity analysis is a better cost-effectiveness principle in general, but it becomes 
especially relevant in situations of crisis. This additional consideration should provide 
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NICE and other governmental bodies with a reason to move to a cost-equity analysis and 
abandon the simple cost-effectiveness principle. Briefly, our main argument is that there 
is something special about a crisis where it is even more important to think in cost-equity 
terms: A crisis will exacerbate and magnify the consequences of societal injustices on 
health. We illustrate this point by focusing on BAME communities, drawing on evidence 
which shows that racism is a cause of them being disproportionally affected by the 
COVID crisis and the corresponding disinvestment of some services.  
 
WHAT IS THE PURPOSE OF COST-EFFECTIVENESS ANALYSIS AND 
IS IT FAIR?  
 
Conducting a cost-effectiveness analysis when human life is at stake may seem 
cruel, inappropriate, based merely on rational utilitarian calculus. Human life, after all, 
has a dignity and not a price, as Kant famously argued in his Groundwork of the 
Metaphysics of Morals. But is this true in our society? First of all, the NHS has always 
placed a price on human life. Since the introduction of NICE this has been made explicit, 
with cost thresholds beyond which an intervention will likely not be made available to 
the public even if it means that people will die. For a heart-breaking account of how 
NICE makes decisions of what treatments can be introduced in the NHS we recommend 
the documentary “The Price of Life”.8 This is devastating, and it may seem unfair and 
unseemly: how can a national public body intentionally decide to withhold treatment 
from people who would otherwise suffer or die prematurely?   
In spite of this, the argument we put forward, in what follows, is that the alternative 
to cost-effectiveness analysis is much worse. By ignoring the reality of our economic 
system, we will end up doing more harm than good.  
The NHS, and NICE, have been introduced to ensure that everyone has a fair chance 
of accessing shared health care services, and not only the privileged members of society. 
NICE’s decisions are transparent and consistent, based on the best available evidence, 
and they often produce new revised guidelines to make sure the process is fair for 
everyone.  What normatively justifies its existence and makes it attractive is precisely its 
concern with issues of fairness.9 
  NICE’s guidelines are fundamentally based on egalitarian principles. It does not 
discriminate based on age, gender, class or wealth. The idea of cost-effectiveness analysis 
is to maximize aggregated health benefits, regardless of how these benefits are distributed 
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across the population—it assumes “distributive neutrality”.10 Another reason to care 
about the cost-effectiveness principle is because it takes issues of opportunity costs 
explicitly into account. That is, it tells us in a transparent way the amount of health that 
may be sacrificed when an expensive treatment is approved.  
Despite the advantages of cost-effectiveness analysis, compared to an unplanned 
allocation of resources, we argue that under the current circumstances this approach is 
not egalitarian enough and we have reasons to weight units of health differently across 
social groups. But how can we identify these social groups and the disease areas we 
should prioritise? One major flaw of NICE decision-making process is that, when they 
approve a certain expensive intervention, say nothing about the displaced activities: we 
thus do not know the type of health or whose health will be sacrificed. Crucially, we do 
not know who the losers are. 
Fortunately, Love-Koh et al.11 and Claxton et al.,12 at the University of York, have 
done an impressive work identifying which activities are likely to be displaced and how 
these changes affect different social groups when NICE, perhaps under pressure from 
stakeholders and pharmaceutical companies, approves an intervention which the NHS 
cannot afford from its current budget. The answer is not that the NHS budged will be 
increased—it almost never is, and the growing economic crisis will not help. Instead, 
treatments which improve life expectancy and quality of life at a much lower cost will 
be made unavailable to NHS patients. Claxton estimates that the main disease areas 
displaced in the past have been cancer, mental illness, circulatory disease, respiratory and 
neurological diseases. Love-Koh et al. similarly conclude that “the health effects from 
NHS expenditure changes are produced largely through disease areas in which 
individuals from more deprived areas account for a large share of health care utilization, 
namely, respiratory and neurologic disease and mental health”.11  
But should we expect the same after the pandemic? Will the same type of 
disinvestment take place and will it continue to affect the same deprived social groups? 
We believe that the current crisis has made this kind of prediction difficult and uncertain. 
This is for three reasons. One limitation of standard cost-effectiveness analysis is that it 
focuses on opportunity costs that fall exclusively on the NHS and social care budgets. In 
order to correctly evaluate a public health intervention during a national emergency we 
ought to take a wider social perspective on costs and benefits and therefore we would 
need to consider the health, non-health benefits and opportunity costs which fall on 
different sectors. An intervention may not produce sufficient health benefits to justify the 
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additional costs placed on the NHS budget; however, a programme which introduces 
COVID-19 vaccination in the general population will result in positive externalities and 
benefits outside the health sector that can make the intervention more appealing.  
Public spending on the COVID-19 interventions so far has reached £190 billions in 
July. This figure already exceeds the entire health budged for 2020-2021.13 It would be 
deceptive to think that just because the government did not carry out a cost-effectiveness 
analysis during the pandemic that considerations of the costs incurred will be forever 
ignored. What is likely to happen and has already started is that other budgets are reduced 
(as of November, overseas aid and public sector pay) or the deficit will increase and this 
debt will eventually be passed onto the taxpayers (in the form of increased taxation or 
inflation), who in turn will become poorer economically, which again will have an impact 
on health. Another issue to consider which cannot be fully addressed here, is the fact that 
the more we spend now the less we have available for future emergencies unless, 
somehow, Gross Domestic Product raises quickly. This kind of opportunity cost should 
also be taken into account because it is, after all, taking resources from use in a future 
pandemic that could be even worse.  
Finally, another source of uncertainty in making predictions about which groups 
bear the opportunity costs of COVID-19 spending comes from the fact that changes 
which were introduced in the healthcare system may be retained, and these changes may 
save money in the long run. One such example is the telehealth—GP consultation via 
phone or internet which may to be cost-saving. Another attractive change announced 
recently by the minister of health is that the NHS Covid testing system could be used for 
fighting the seasonal flu, which would reduce the community spread of influenza.14 This 
could save money from reducing absenteeism at work due to illness.  
Regardless of the reasons for uncertainty, given the magnitude of spending and 
services changes under the pandemic there is an imperative to carefully consider 
displaced activities to minimise population health losses caused by displaced activities 
which, as Claxton and colleagues have shown, regularly occurs even in circumstances 
when the cost-effectiveness of spending has been considered.  
We turn now to argue that a cost-equity analysis is the right way to move forward. 
It is an approach that considers both the magnitude of the losses and who stands to lose, 
and without such explicit considerations of fairness the consequences of discrimination 
on poor health is worsened in a crisis. In doing this, we defend the claim that it is 
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sometimes permissible not to maximise health in the population in order to protect values 
such as justice.  
 
      COVID IMPACT ON BAME COMMUNITIES  
 
Health economists have already argued that equity concerns should be part of 
economic evaluations.15 They have focused their attention on economic deprivation and 
socio-economic status as the main unfair social determinants of health. To date, this 
appeal has been unsuccessful, and NICE continue to reject introducing explicit equity 
weights in order to prioritise treatments for certain groups of people.16 We believe that 
the crisis brings to the foreground the need for a definite move to cost-equity analysis 
that NICE should consider seriously.   
Evidence from Public Health England (PHE)17 published in June this year shows 
that COVID-19 has not impacted all population groups equally. In fact, there is a great 
disparity in mortality and morbidity between BAME groups and their British white 
counterparts. BAME communities do worse in terms of higher death rates (four times 
higher in this period), higher probability of infection and higher risk of developing 
serious complications once infected. Why is this the case? Socio-economic deprivation 
is statistically correlated with excess mortality and morbidity from COVID-19 and 
BAME communities are more likely to come from poorer socio-economic backgrounds 
and work in jobs where infection risk is higher. There is also strong evidence that BAME 
groups suffer from health conditions which are likely to increase the severity of disease 
and therefore cause death—obesity, diabetes, hypertension, smoking, and mental health 
illness.17  
This is not news, of course, but only proves what we suspected all along: 
longstanding inequalities are made worse by the COVID-19 crisis, will further 
disadvantage those in poor health, and will worsen socioeconomic deprivation in a 
country which is already very unequal. We know this because research spanning for over 
thirty years from health economists shows that there is a steep gradient in life expectancy 
and quality of life between the rich and the poor in the UK. For instance, researchers at 
the Centre for Health Economics at York show that “The richest fifth of people in 
England can expect to live at least 12 more years of life in full health than the poorest 
fifth”.18 Furthermore, these stark health inequalities are stubbornly difficult to improve 
since they are rooted in structural inequalities related to wealth, income, socio-economic 
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background, level of education, and occupation—known as the “the social determinants 
of health”.19 Therefore, the rise in health inequality from COVID-19 is likely to persist 
long after the pandemic is over, further entrenching social inequalities. 
We choose to focus on the PHE report because they include in their analysis all the 
known social determinants of health.  Three things came as a great surprise to us, which 
we believe constitute original findings. First, after controlling statistically for age, gender 
and economic deprivation, ethnicity is statistically significant, that is, BAME 
communities were disproportionately affected by COVID-19. 
The second surprising finding  was that poor mental illness is a big risk factor for 
COVID-19 severity and death. BAME communities and people from deprived 
socioeconomic backgrounds are more likely to develop mental illness and less likely to 
have access to NHS mental health support, according to the Adult Psychiatric Morbidity 
Survey.20 For example, only 6.5% of black men receive mental health treatment for their 
illness compared to 14.5% for white men. 
Finally, a plausible explanation for the high mortality and morbidity is racism (see 
section of the report on “Racism, discrimination, stigma, fear and trust”). Consequently, 
PHE recommends that ethnicity should be a specific concern in future policy actions: 
“Fully funded, sustained and meaningful approaches to tackling ethnic inequalities must 
be prioritised”. 
We defend the claim that BAME communities should be favoured in economic 
analysis because we have reasons to believe their disadvantage is inequitable. (1) First, 
as proven by the PHE report, they have poorer health outcomes even after controlling for 
age and gender. What makes (1) inequitable is that a likely explanation of the different 
health outcomes is racism, and therefore unfair discrimination. (2) Secondly, BAME 
communities have poorer socioeconomic circumstances which lead to poorer health 
outcomes. To the extent that these disadvantages are the result of unfair social 
circumstances, they constitute a further inequity. The policy response may have 
exacerbated this inequality on account that some of the health services temporarily 
displaced (cancer treatment i and mental health services) are mostly needed by lower 
socioeconomic groups (see Love-Koh et al. 2020) and by BAME communities.  In the 
                                                        
i
 There is also evidence that the BAME communities in the UK relied the most on cancer treatment as 
they are at higher risks of developing advanced cancers and have poorer survival rates compared to the 
white British.21 
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next section we propose that introducing cost-equity analysis in the future has the 
potential to correct for this unfair discrimination and prevent further disadvantage. 
 
HOW SHOULD WE MOVE FORWARD? 
 
We need a very good reason to justify a reduction in population health. One such 
reason, we suggest, is that it is sometimes permissible to sacrifice the value of 
maximising health in order to uphold other values, i.e., justice. We cannot ignore that the 
members of the BAME communities are already systematically disvalued in our society 
and thus “an adequate engagement with health equity also requires that the considerations 
of health be integrated with broader issues of social justice and overall equity”.22 
Therefore, we propose that measures aimed at improving health in general should be 
implemented such that they always benefit the most the worse-off groups of society in a 
way which compensates for their unfair disadvantage.   
How can we then aim at reducing health inequities between groups and still 
incorporate cost-effectiveness principles? We suggest that the government should move 
to adopt a cost-equity analysis, where equity weights on health can be introduced to give 
some priority in our policies to vulnerable groups. This in effect would translate to 
accepting a higher threshold for interventions which directly impact the health of the 
BAME communities.  
One difficulty is how much priority can and should be given to reducing unjust 
health inequalities. How much more weight should we place on an additional unit of 
health gain if we are to make good the balance of health inequality between social 
groups?23 We suggest that, given that the question is how to allocate resources from a 
publicly funded system, the answer may need to incorporate the view of the general 
public.23 There is a lot of support in the empirical literature for the claim that people do 
care about health inequalities.10,23 We need to know whether people would prioritise 
patients from vulnerable groups and, above all, to what extent the citizenry is willing to 
redirect NHS resources from highly cost-effective treatments to those which will reduce 








BAME communities already suffer from poorer health in everyday medical contexts 
through no fault of their own. What this crisis has shown is that they are also the ones 
most vulnerable during exceptional medical emergencies. However, these two things are 
not independent. Their poor health during normal conditions, which has its roots in unfair 
social disadvantage, puts them at high-risk during pandemics. The existence of health 
inequalities therefore gives us additional reasons to care about redressing social 
injustices. We need to correct for this unjustified inequality by introducing a type of cost-
effectiveness analysis which takes equity into account.  
The solution is not to ignore the rule of opportunity cost. If we want to protect the 
BAME communities in the future and thus reduce health disparities between social 
groups, the government should consider and make explicit the displaced treatments and 
programmes. They should make sure they do not disinvest from the very activities that 
promote the health of the BAME communities, as already acknowledged by PHE: “Local 
and national policy initiatives will need to be sensitive to BAME communities to ensure 
existing health and economic inequalities are not widened due to the extraordinary 
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